Browsing: Africa’s health sector

Kenyan health startup Afya Rekod partners with Medi-Science to improve personal health data in Africa and Europe www.theexchange.africa

An analytical telemedicine system is provided by MediLiVes; the system aims to reduce the time and money required for medical tests.

MediLiVes is a forward-thinking project that provides telemedicine solutions that are one-of-a-kind and cutting-edge.

One of the fields experiencing the most rapid expansion worldwide is telemedicine, which is built on technology that allows for a patient’s health status to be monitored from a distance.…

Mental health- verywellmind

Suicide has become a major urgent public health crisis in the continent and has led to the premature death of especially productive youth in their prime—the future builders of the continent.

According to the World Health Organization (WHO), more than 700,000 persons die by suicide every year globally and it is the fourth leading cause of death among 15 to 29-year olds.  From job losses, trauma, abuse, mental health disorders and barriers to accessing health care these are just but a few triggers to committing suicide by many millennials. …

Vaccine - WHO

Kenya and Uganda are among the countries selected for the Phase 1 clinical trial of an HIV vaccine.  According to the Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT), the first dose will be given in Lusaka, Zambia while Kenya and Uganda will receive the vaccines in a few weeks.  

Dr. William Kilembe, project director of the Center for Family Health Research in Zambia (CFHRZ) and trial principal investigator, said that international partnerships are crucial in developing and evaluating HIV vaccine candidates in countries and communities where HIV vaccines will ultimately have the greatest public health impact. 

“CFHRZ is proud to be part of the consortium evaluating HIVconsvX and to deliver the first dose of this experimental HIV vaccine in the HIV-CORE 006 trial,” he said.  

The trial will see 88 healthy, HIV-negative adults, aged 18-55, who are considered not to be at high risk of infection, receive one